Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
Clinical and Molecular Hepatology · 01.07.2024 · 30 (3) · 345-359
DOI: 10.3350/cmh.2023.0553 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.07.2024. Verfasst von Young Eun Chon und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam, Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Phenylurea Compounds, Sorafenib. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Roche, Dong-A ST, Boryung Pharmaceuticals.
Abstract (Originalsprache)
Background/Aims: Atezolizumab plus bevacizumab (ATE+BEV) therapy has become the recommended first-line therapy for patients with unresectable hepatocellular carcinoma (HCC) because of favorable treatment responses. However, there is a lack of data on sequential regimens after ATE+BEV treatment failure. We aimed to investigate the clinical outcomes of patients with advanced HCC who received subsequent systemic therapy for disease progression after ATE+BEV.
Methods
This multicenter, retrospective study included patients who started second-line systemic treatment with sorafenib or lenvatinib after HCC progressed on ATE+BEV between August 2019 and December 2022. Treatment response was assessed using the Response Evaluation Criteria in Solid Tumors (version 1.1.). Clinical features of the two groups were balanced through propensity score (PS) matching.
Results
This study enrolled 126 patients, 40 (31.7%) in the lenvatinib group, and 86 (68.3%) in the sorafenib group. The median age was 63 years, and males were predominant (88.1%). In PS-matched cohorts (36 patients in each group), the objective response rate was similar between the lenvatinib- and sorafenib-treated groups (5.6% vs. 8.3%; P=0.643), but the disease control rate was superior in the lenvatinib group (66.7% vs. 22.2%; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- Department of Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Förderung
- Roche
- Dong-A ST
- Boryung Pharmaceuticals
Zitieren
APA
Chon, Y. E., Kim, D. Y., Kim, M. N., Kim, B. K., Kim, S. U., Park, J. Y., Ahn, S. H., Ha, Y., Lee, J. H., Lee, K. S., Kang, B., Kim, J. S., Chon, H. J., & Kim, D. Y. (2024). Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study. Clinical and Molecular Hepatology, 30(3), 345-359. https://doi.org/10.3350/cmh.2023.0553
Vancouver
Chon YE, Kim DY, Kim MN, Kim BK, Kim SU, Park JY, et al. Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study. Clinical and Molecular Hepatology. 2024;30(3):345-359. doi:10.3350/cmh.2023.0553
BibTeX
@article{Chon2024,
author = {Chon, Young Eun and Kim, Dong Yun and Kim, Mi Na and Kim, Beom Kyung and Kim, Seung Up and Park, Jun Yong and Ahn, Sang Hoon and Ha, Yeonjung and Lee, Joo Ho and Lee, Kwan Sik and Kang, Beodeul and Kim, Jung Sun and Chon, Hong Jae and Kim, Do Young},
title = {Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study},
journal = {Clinical and Molecular Hepatology},
year = {2024},
volume = {30},
number = {3},
pages = {345--359},
doi = {10.3350/cmh.2023.0553}
}
EUVIMED